Answer
Eculizumab’s mean elimination half-life was 11.3 ± 3.4 days, estimated using a one-compartment model after multiple doses in 40 patients with paroxysmal nocturnal haemoglobinuria (PNH).
Sources for this answer
- Soliris 300 mg concentrate for solution for infusionAlexion Pharma UK Ltd · emc · SmPC §5.2 Pharmacokinetic properties · Version 29Document updated
Sources checked